Pluto Immunotherapeutics is a biotechnology company developing next-generation cell therapies for oncology and autoimmune diseases.
Market:
Pluto is developing a pipeline of engineered cell therapies targeting hematologic malignancies, solid tumors, and autoimmune diseases. The company is advancing both autologous and next-generation allogeneic approaches to expand patient access to transformative cellular immunotherapies while addressing major limitations of current treatments, including manufacturing complexity, durability, and accessibility.
Technology:
Pluto’s proprietary platform integrates advanced CAR engineering with innovative T-cell manufacturing technologies to generate highly functional therapeutic T cells with improved persistence, potency, and safety. The company is also developing an induced pluripotent stem cell (iPSC)-derived platform designed to enable scalable, off-the-shelf cellular therapies with sophisticated gene engineering capabilities for future clinical applications.
Advantages:
- Proprietary platform for engineering highly functional therapeutic T cells
- Pipeline spanning oncology and autoimmune diseases
- Expertise in both autologous and allogeneic cell therapy development
- Advanced cellular engineering designed to enhance potency, persistence, and safety • Scalable manufacturing strategies to improve patient access
- Long-term vision for renewable, gene-edited off-the-shelf cell therapiesBest-in-class technology for generating mature T cells from a renewable source of induced pluripotent stem cells (iPSC)
Development Stage:
- Multiple preclinical cell therapy programs
- Lead therapeutic candidate in IND-enabling development
- Proprietary platform technologies supporting future pipeline expansion
Select Publications:
- Chen et al. Superior anti-tumor activity of a rationally engineered hybrid CD20 CAR-T cell. Cancer Immunology Research (2023)
- Montel-Hagen et al. Organoid-Induced Differentiation of Conventional T Cells from Human Pluripotent Stem Cells. Cell Stem Cell (2019)
- Seet et al. Generation of Mature T Cells from Human Hematopoietic Stem and Progenitor Cells in Artificial Thymic Organoid. Nature Methods (2017)
Contact:
Email: amelie@plutoimmuno.com
- Anaco
- CDR3 Therapeutics, Inc.
- Dalton Bioanalytics
- Diatom Biolab
- Eximius Diagnostics
- Giant BioSystems
- Hikari Medical Technologies
- ImmunoVec
- MedStat AI Inc.
- Mervyn's Petcare, Inc.
- Meteor Biotech, LLC
- My Block Skin, Inc.
- Nanomega CryoAI
- NEXT-TFX, Inc.
- Paralos Bioscience Inc.
- Pelage Pharmaceuticals
- Pluto Immunotherapeutics
- Prosper DNA
- Protean Research, Inc.
- Purpose Bio
- RaizDx
- RiboForge
- Saku Biosciences, Inc.
- SolGrapH, Inc.
- Sorriso Pharmaceuticals
- Thermeutics, Inc.
- Vault Pharma
- Veergen, Inc.
- Yuyu Bio, Inc.